Tag: UZEDY
MedinCell – Partner Teva provides 2024 sales forecast for UZEDY™ and provides update on long-acting injectable olanzapine treatment candidate – 01/31/2024 at 10:00 p.m.
· UZEDY revenue forecast for Teva in 2024: ~$80 million · Ongoing phase 3 of Olanzapine LAI: l675 patients (recruitment completed), 62% of 3,600 planned injections completed, no PDSS (post-injection…
MedinCell Partner Teva Announces Successful Launch of UZEDY™ – 2023-08-02 22:52
MedinCell Partner Teva Announces Successful Launch of UZEDY™ Euronext: MEDCL – Montpellier – France – August 2, 2023 – 10:00 p.m. ________________________________________________________________________________ Richard Francis, Chairman and Chief Executive Officer of…